PolyNovo

PolyNovo grew out of dermal-regeneration research begun in 2004 at the Royal Adelaide Hospital, where surgeons and materials scientists were looking for a fully synthetic alternative to the animal-derived dermal-regeneration templates then in clinical use for burns and complex soft-tissue reconstruction. The result — NovoSorb Biodegradable Temporising Matrix, or BTM — is a two-millimetre synthetic polyurethane bilayer that is implanted into a full-thickness wound bed to serve as a temporary dermal template, and which the patient’s own tissue then remodels into a functional dermis as the matrix biodegrades. First used on a human patient in a 2014 pilot burn trial in Adelaide, BTM is now approved and reimbursed across Australia, the United Kingdom, several European jurisdictions, and the United States, and the firm operates as a publicly traded biomaterials company on the Australian Securities Exchange.

The firm designs, manufactures, and supports the NovoSorb family of biodegradable polyurethane dermal templates and related regenerative devices for use in reconstructive surgery of extensive burns, degloving and crush injuries, necrotising infections, oncological reconstructions where a free-flap donor is unavailable or contraindicated, and complex diabetic and vascular wounds. NovoSorb BTM is the principal commercial product and is joined by NovoSorb MTX (a matrix variant) and a growing pipeline of applications in the same polyurethane-chemistry platform. Manufacturing is concentrated at the Port Melbourne facility; commercial operations are direct in the principal reimbursed markets and distributor-supported elsewhere.

Two things distinguish PolyNovo among reconstructive-biomaterials firms: the categorical decision to build the entire commercial platform on a single synthetic polyurethane chemistry, and the clinical evidence base that decision has produced. The competing dermal-regeneration templates on the American market are collagen-based and animal-derived — a category whose infection risk, cost structure, and supply-chain vulnerabilities were the specific problems the Adelaide team set out to answer. NovoSorb is fully synthetic, offers no substrate for bacterial growth, and has produced, over the last decade, one of the more substantial single-product evidence bases in the reconstructive-surgery literature, from the initial pilot burn trial through prospective clinical studies and long-term scarring-outcome cohorts.